Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + amoxicillin dual therapy versus susceptibility-based tailored rescue therapy for Helicobacter pylori infection
ChiCTR2200060559Phase 4Not yet recruiting
- Sponsor
- Army Medical University
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vonoprazan and amoxicillin in Helicobacter pylori infection (2 arms), sponsored by Army Medical University. Primary endpoint: Eradication rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
vonoprazanamoxicillin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2200060559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060559.